found that the combination of pazopanib and metformin effectively inhibits tumor cell proliferation by suppressing signaling pathways such as phosphorylated Akt/ nuclear factor kappa‐light‐chain‐enhancer of activated B cells/ signal transducer and activator of transcription 3 (p‐Akt/NF‐κB/IL‐6/STAT3) and hypoxia‐inducible factor 1‐alpha/ vascular endothelial growth factor/ (HIF1α/VEGF), thereby reducing the activity levels of Akt and NF‐κB, decreasing Interleukin‐6 (IL‐6) secretion, and inhibiting STAT3 signal transduction, which collectively weakens the pro‐inflammatory microenvironment. This evidence concerns the gene AKT1 and neoplasm.